Prestige Biopharma's Study Confirms HD204 as a Strong Biosimilar to Avastin for Lung Cancer Prestige Biopharma has unveiled significant topline findings from their SAMSON-II study, showcasing HD204 as a promising biosimilar to Avastin for lung cancer treatment.

Prestige Biopharma's Study Confirms HD204 as a Strong Biosimilar to Avastin for Lung Cancer #Singapore #Avastin #Prestige_Biopharma #HD204

Prestige Biopharma Collaborates with Biosidus for Tuznue® Launch in Latin America Prestige Biopharma partners with Biosidus for exclusive rights to Tuznue® commercialization across Latin America, enhancing treatment access.

Prestige Biopharma Collaborates with Biosidus for Tuznue® Launch in Latin America #Argentina #Buenos_Aires #Prestige_Biopharma #Biosidus #Tuznue